The FDA has taken significant action against ImmunityBio, issuing a warning letter that highlights misleading claims in the promotion of its cancer therapy, Anktiva. This move raises important regulatory and commercial concerns within the biopharmaceutical landscape.
Promotional Missteps
The agency’s Office of Prescription Drug Promotion (OPDP) specifically criticized a direct-to-consumer television advertisement and a podcast featuring company executives. These promotional materials allegedly conveyed false or misleading information regarding the efficacy and approved usage of Anktiva, leading to concerns about the integrity of communication in healthcare marketing.
According to the FDA, the advertisements suggested that Anktiva could cure cancer, prevent recurrence, and be effective against various tumor types. These assertions were deemed unsupported by the available clinical evidence or the drug’s official labeling.
Approved Indications and Misrepresentation
Anktiva received approval in April 2024 for a specific condition: Bacillus Calmette-Guérin-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ, but only when used in combination with BCG. The FDA emphasized that the promotional content failed to accurately communicate this limited indication and instead implied a broader range of applicability, misleading potential patients about the drug’s capabilities.
Administration Concerns
The FDA’s warning also pointed to discrepancies regarding how Anktiva is administered. While the drug is sanctioned for intravesical use, the promotional content included suggestions that it could be injected, including subcutaneous administration. Such claims could lead to patient misconceptions about safe and effective use, particularly since no evidence supports alternative administration routes.
Risk Communication Lapses
Regulatory scrutiny also fell on the omission and minimization of risk information in the advertisements. The television spot prominently showcased benefit claims but relegated risk disclosures to the end, accompanied by visual cues that suggested the ad had concluded. The podcast entirely neglected to address safety risks, creating a misleading impression about the therapy’s safety profile.
Previous Warnings and Regulatory Oversight
The FDA noted that this is not the first instance of concern regarding ImmunityBio’s promotional practices. Previous communications in 2025 and early 2026 had already flagged similar issues, indicating a pattern that the agency finds troubling.
As ImmunityBio seeks to commercialize Anktiva—reporting global sales of $113 million in 2025 and projecting growth to approximately $217.6 million—such regulatory scrutiny could have far-reaching implications for the company’s marketing strategies and overall reputation.
Response from ImmunityBio
In response to the FDA’s warning letter, ImmunityBio stated that it is reviewing the document and intends to respond within the required 15 working days. The company faces the challenge of aligning its promotional practices with the FDA’s expectations while maintaining its market presence.
Disconnect Between Claims and Evidence
At the heart of the FDA’s concerns lies a significant disconnect between the clinical evidence supporting Anktiva and the broader claims made in its marketing. The drug’s approval was based on a single-arm study that assessed complete response and duration of response, without a comparator arm that could provide insights into long-term outcomes like disease-free survival. The FDA has indicated that it is not aware of any data that supports claims of curing cancer or preventing recurrence.
Next Steps for Compliance
The FDA has directed ImmunityBio to halt the distribution of misleading promotional materials and to create corrective communications to rectify the impressions created among patients and healthcare providers. Failure to adequately address these issues could lead to additional enforcement actions, including potential seizures or injunctions.
Conclusion
The FDA’s warning to ImmunityBio serves as a critical reminder of the need for accuracy and transparency in pharmaceutical advertising. As the company endeavors to navigate this regulatory landscape, it must prioritize truthful communication to maintain trust with patients and healthcare professionals alike. This situation underscores the importance of aligning promotional efforts with clinical evidence to foster informed decision-making in oncology and beyond.
- Key Takeaways:
- FDA warns ImmunityBio over misleading promotional claims about Anktiva.
- Concerns include misrepresentations of efficacy, administration routes, and risk communication.
- ImmunityBio faces scrutiny as it commercializes Anktiva, emphasizing the need for compliance.
- The situation reflects broader issues of accountability in pharmaceutical marketing.
Read more → www.pharmexec.com